Clinical Trials

Hepatocellular Carcinoma (HCC)

A Phase II, Open-Label, Multicohort, Multicenter Study in Patients with Hepatocellular Carcinoma and Child-Pugh B Cirrhosis

Lung Cancer

A081801 Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Pancreatic Cancer

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Observation Following Curative Intent Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
 

Breast Cancer

The effect of regular physical activity and virtual exercise intervention on physical functions, fatigue, mental health, and disease progression in Metastatic Breast Cancer (MBC)

Lung Nodules

Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percept Nasal Swab Classifier – with Familiarization

Atrial Fibrillation

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG

Cardiometabolic

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

Cardiopulmonary Bypass 

ARTEMIS: RAvulizumab to PRotect PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study

Cardiothoracic Surgery
EMBOLIC PROTECTION IN PATIENTS UNDERGOING HIGH RISK VALVE SURGERY

Cardiothoracic Surgery

The Cryoanalgesia Registry for Pain Management in Post-cardiothoracic Surgery Via Cryoablation of the intercostal nerves Registry (REDUCE Registry)

Coronary Artery Disease

REvascularization Choices Among under-Represented Groups Evaluation (The RECHARGE Trial)

Coronary Artery Disease
A randomized controlled study of the Prevail Drug-Coated Balloon in subjects with in-stent restenosis and a single arm prospectively enrolled study of the Prevail Drug-Coated Balloon for de novo lesions in small vessel disease (Prevail Global)

CV Surgery

Thoracoabdominal Branch Endoprosthesis Post-Approval Study

Electrophysiology
Product Surveillance Registry (PSR) Platform Base Protocol

Breast Cancer

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for Triple-Negative

Colorectal Cancer

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Palbociclib and Cetuximab versus Cetuximab Monotherapy for Patients with CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial

Pancreatic Cancer

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Lung Cancer

A Multicenter Randomized Trial of EBUS-TBNA Versus Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

Electrophysiology
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treatment

Interventional Cardiology
THE MAGENTA ELEVATE™ HIGH-RISK PCI PIVOTAL STUDY

Interventional Cardiology
AGENT Drug-Coated Balloon for STent AvoidANCE in PCI for De Novo Coronary Artery Disease

Breast Cancer
A Phase I/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, and pharmacokinetics of BNT323 in combination with BNT327 in participants with advanced breast cancer.

Breast Cancer
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

Breast Cancer
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy